National Comprehensive Cancer Network
Pharmacy Program:
Educational Events & Programs
NCCN Clinical Practice Guidelines in Oncology Symposium: Breast Cancer
Highlights from a symposium hosted by Duke Comprehensive Cancer Center on September 22, 2008
Presenters
Prognostic Factors
Gary H. Lyman, MD, MPH
Duke Comprehensive Cancer Center
Durham, North Carolina
Primary Treatment: Biopsy and Staging, Surgery, and Radiation
Stephen B. Edge, MD
Roswell Park Cancer Institute
Buffalo, New York
Adjuvant Therapy: Chemotherapy, Hormonal Therapy
Richard L. Theriault, DO
The University of Texas M. D. Anderson Cancer Center
Houston, Texas
Treatment for Advanced Breast Cancer: Chemotherapy, Biologic Therapy, Hormonal Therapy
John H. Ward, MD
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah
Faculty Disclosure Statements
Gary H. Lyman, MD, MPH
Dr. Lyman has disclosed that he has financial interests, arrangements, or affiliations with the manufacturer of products or devices to be discussed in this activity or who may financially support the educational activity. He has received grant/research support from Amgen Inc. and Genomic Health, Inc. He has also served on the product/speakers’ bureau for Amgen Inc.
Dr. Lyman has indicated that his presentation will not include discussion of investigational or unlabeled uses of a product.
Stephen B. Edge, MD
Dr. Edge has disclosed that he has no financial interests, arrangements, or affiliations with the manufacturer of any products or devices to be discussed in this activity or who may financially support the educational activity.
Dr. Edge has indicated that his presentation will not include discussion of investigational or unlabeled uses of a product.
Richard L. Theriault, DO
Dr. Theriault has disclosed that he has financial interests, arrangements, or affiliations with the manufacturer of products or devices to be discussed in this activity or who may financially support the educational activity. He has received grant/research support from and has served as a scientific advisor for Amgen Inc.
Dr. Theriault has indicated that his presentation will not include discussion of investigational or unlabeled uses of a product.
John H. Ward, MD
Dr. Ward has disclosed that he has financial interests, arrangements, or affiliations with the manufacturer of products or devices to be discussed in this activity or who may financially support the educational activity. He has served as a consultant for Agendia BV and Myriad Genetic Laboratories, Inc.
Dr. Ward has indicated that his presentation will not include discussion of investigational or unlabeled uses of a product.
Program Overview
The NCCN Clinical Practice Guidelines in Oncology™ consist of a comprehensive set of guidelines detailing the sequential management decisions and interventions for the malignancies that affect 97% of all patients with cancer. Developed by faculty at NCCN Member Institutions using a consensus-based process with explicit review of pertinent data, the guidelines panels develop over 100 separate pathways. The NCCN Breast Cancer Guidelines Panel has developed and continually updates algorithms for management of non-invasive and invasive breast cancer. This activity is an in-depth analysis of the evidence and clinical decision making that led to the development of these guidelines. Topics include diagnosis, staging workups with discussion of prognostic markers, local therapy, and the use of hormonal, cytotoxic and biologic therapies in the adjuvant, neoadjuvant, and metastatic settings.
Educational Objectives
Following this activity, participants should be able to:
- Explain clinical algorithms for the treatment of breast cancer
- Describe the diagnostic and staging work-up for each stage of breast cancer
- Identify the role of prognostic markers in breast cancer
- Compare survival data for three approaches to local therapy for DCIS
- Describe the precepts of surgery and radiation in the management of Stage 0, I, II, and III breast cancer
- Outline the current recommendations for hormonal and cytotoxic agents as adjuvant therapy for Stage I and II breast cancer
- Recognize the role of neoadjuvant chemotherapy in Stage II and III breast cancer
- Differentiate agents available for the treatment of advanced or recurrent breast cancer including chemotherapy, biologic therapy, and hormonal therapy
Intended Audience
This educational activity is designed to meet the needs of physicians, nurses, and other clinical professionals who manage patients with cancer.
Activity Instructions
Continuing education credit will be awarded to participants who listen to the presentation and complete the evaluation. Participants should review the learning objectives and faculty disclosure statements prior to listening to a presentation in its entirety. You must be connected to the Internet in order to review and complete the evaluation form. A statement of credit will be electronically generated once you complete the evaluation form. To receive credit, this activity must be completed no later than December 23, 2009. There is no fee for participating in this activity.
Accreditation Information
Physicians
The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.
NCCN designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurses
This activity is approved for 2.0 contact hours. National Comprehensive Cancer Network is an approved provider of continuing nursing education by PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation or PA Nurses approval or endorsement of any product.
Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.
Release date: December 23, 2008
Expiration date: December 23, 2009
Commercial Support
Supported by educational grants from Abraxis BioScience, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Genentech BioOncology, GlaxoSmithKline, Novartis Oncology, Pfizer Inc, Roche, and sanofi-aventis US
E-mail
Print
Mark
|
|
|
|
|
|
|
||